PMGC HOLDINGS INC. Capitalized Contract Cost, Impairment Loss
PMGC HOLDINGS INC. (ELAB) reported Capitalized Contract Cost, Impairment Loss of $500.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CapitalizedContractCostImpairmentLoss · last filed 2026-03-30
- PMGC HOLDINGS INC. capitalized contract cost, impairment loss for fiscal 2025 was $500.00K.
| Period end | Capitalized Contract Cost, Impairment Loss 12 month |
|---|---|
| 2025-12-31 | $500.00K 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B |